The effects of probiotic bacteria on glycaemic control in overweight men and women: a randomised controlled trial

Ivey, Kerry L.; Hodgson, Jonathan M.; Kerr, Deborah A.; Lewis, Joshua R.; Thompson, Peter L.; Prince, Richard

doi:10.1038/ejcn.2013.294

Cited by 77 publications

(71 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An abnormal fasting insulin level indicates a potential risk of developing diabetes; thus, it is crucial for both patients and health-care professionals to take precautionary measures to prevent diabetes when abnormal fasting insulin levels are presented [67]. In the 6 reviewed studies, the authors did not find significant fasting insulin differences between the intervention groups and control groups [38,43,47,50,57,66]. Except for the study without original data conducted by Chung et al [47].…”

Section: Change Of Biochemical Indicatorsmentioning

confidence: 66%

“…15). HbA1c was only evaluated in 3 studies [47,56,66]. Since there were no original data in the report of Chung et al [47]; thus, the meta-analysis was performed based on the remaining 2 studies (199 participants) [56,66].…”

Section: Change Of Biochemical Indicatorsmentioning

confidence: 99%

“…Among the remaining 7 studies, 5 of them found no significant differences in fasting glucose or blood glucose in between-group comparisons [38,43,50,55,57]. In the 2014 4-arm study by Ivey et al [66], the researchers used a 4-arm approach: (A) probiotic yogurt plus probiotic capsules, (B) probiotic yogurt plus placebo capsules, (C) control milk plus probiotic capsules, and (D) control milk plus placebo capsules. The author found significant differences in blood glucose between group B and D (p < 0.037), and no significant difference was found between group A and C. To conduct the meta-analysis, the reviewers standardized the unit-of-measurement prior to computations.…”

Section: Change Of Biochemical Indicatorsmentioning

confidence: 99%

See 2 more Smart Citations

Probiotic Foods and Supplements Interventions for Metabolic Syndromes: A Systematic Review and Meta-Analysis of Recent Clinical Trials

Dong

Chen

et al. 2019

Ann Nutr Metab

View full text Add to dashboard Cite

Background: Individual clinical trials suggested that when treated with probiotic foods or supplements with Lactobacillus and Bifidobacterium, specific symptoms of metabolic syndrome (MetS) could be alleviated, but the results have been inconclusive. Aims: The objective of the present meta-analysis was to use anthropometric and biochemical as indicators to evaluate the efficacy of using these probiotic foods or supplements among individuals with MetS. Methods: PubMed, Cochrane Library, and CINAHL Plus were used to collect randomized controlled trials (RCTs) studies published from January 2000 to January 2018. Studies were included if they had at least one of the following outcome measurements: body mass index (BMI), waist circumference, hip circumference, waist-to-hip ratio, body fat mass (BFM), body fat percentage (BFP), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting glucose, fasting insulin, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, and/or hemoglobin A1c (HbA1c). Results: The 356 records were identified during the literature search, of which only 18 met the selection criteria. The 18 RCTs with a total of 1,544 participants were included in this analysis. This meta-analysis indicated that there were no significant differences of BMI, BFM, waist circumference, hip circumference, waist-to-hip ratio, SBP, DBP, fasting glucose, fasting insulin, TC, HDL-C, HbA1c, or triglycerides between the intervention and control groups. Significant standardized mean net differences were found in the BFP and LDL-C between the intervention and control groups. Conclusions: The results indicated that probiotic food and supplement with Lactobacillus and Bifidobacterium could be used as interventions to improve specific anthropometric and biochemical outcomes among individuals with MetS. However, probiotic treatment alone could not reduce overall health risks. In addition, there were methodological drawbacks among reviewed studies, and further research is needed.

show abstract

Section: Change Of Biochemical Indicatorsmentioning

confidence: 66%

Section: Change Of Biochemical Indicatorsmentioning

confidence: 99%

Section: Change Of Biochemical Indicatorsmentioning

confidence: 99%

See 1 more Smart Citation

Probiotic Foods and Supplements Interventions for Metabolic Syndromes: A Systematic Review and Meta-Analysis of Recent Clinical Trials

Dong

Chen

et al. 2019

Ann Nutr Metab

View full text Add to dashboard Cite

show abstract

“…Several clinical trials have shown the effect of probiotics on the reduction of glucose, insulin, HbA 1c and other glycemic factors for type 2 diabetes mellitus (T2DM) [10][11][12][13][14][15][16][17][18][19] and other diabetes or metabolic syndrome (defined as MS) [9,[20][21][22][23][24][25][26]. However, their dosages, bacterial strains and time of therapy were short of homogeneity.…”

Section: Introductionmentioning

confidence: 99%

Multiple effects of probiotics on different types of diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials

Wang

Juan

et al. 2017

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

Background: A systematic review and meta-analysis was designed to evaluate the effect of probiotics on diabetes and its associated risk factors. Methods: We systematically searched the Cochrane Library, PubMed, EMBASE and Web of Science to June 2016. We also hand-searched the citation lists of included studies and previously identified systematic reviews to identify further relevant trials. Our primary outcome variables included glucose, glycated hemoglobin (HbA 1c ) and insulin. The pooled standardized mean difference was used to compare the effect between the probiotics and controlled groups, and the pooled standardized mean difference effect size with a 95% confidence interval (CI) was estimated using a random-effect model. Heterogeneity was assessed with Cochran's Q and Higgins I 2 tests. Two reviewers assessed trial quality and extracted data independently. The analysis and bias for each included study was performed and assessed using Review Manager 5.2. Results: Eighteen randomized, placebo-controlled studies (n = 1056 participants, 527 consuming probiotics, 529 not consuming probiotics) were included for analysis. Comparing the probiotics groups with the control groups, there were statistically significant pooled standardized

show abstract

“…Исследования по пробиотическим вмеша-тельствам у человека выявили положительное влияние этих подходов на метаболизм глюкозы [59]. Например, в течение 6-недельного рандо-127 мизированного плацебо-контролируемого ис-следования среди 60 здоровых с избыточным весом жителей Индии смесь пробиотика VSL#3 снижала системные уровни глюкозы и инсулина в крови [60].…”

Section: терапевтический потенциал манипулирова-ния кишечной микробиоunclassified

Obesity and Metabolic Syndrome: Pathophysiological Role of Gut Microbiota and Potential of the Alternative Therapy

Айтбаев¹,

Муркамилов²

2017

Kompleks. probl. serdečno-sosud. zabol.

View full text Add to dashboard Cite

В обзоре представлены данные, характеризующие современное состояние знаний о связи между ки-шечной микробиотой, ожирением и метаболическим синдромом. Обсуждается патофизиологическая роль кишечной микробиоты в развитии ожирения и метаболического синдрома. Рассматриваются потенциаль-ные возможности альтернативной терапии для контроля потребления энергии и снижения распространён-ности ожирения и метаболического синдрома.Ключевые слова: ожирение, метаболический синдром, кишечная микробиота, субклиническое воспа-ление, транслокация фекальной микробиоты, пробиотики, пребиотики. The review presents data describing the current state of knowledge about the link between gut microbiota, obesity and metabolic syndrome. Pathophysiological role of gut microbiota in the development of obesity and metabolic syndrome is discussed. Potential of alternative therapy in controlling energy consumption and reducing the prevalence of obesity and metabolic syndrome is considered. OBESITY AND METABOLIC SYNDROMEKey words: obesity, metabolic syndrome, gut microbiota, low-grade inflammation, fecal microbiota transplantation, probiotics, prebiotics. НИИ КПССЗ имеет большой опыт в разработке изделий для сердечно-сосудистой хирургии, в частности биопротезов кла-нов сердца и сосудов. С 2010 года под руководством академика РАН л. С. Барбараша начаты исследования по созданию био-зорбируемых сосудистых протезов малого диаметра. Основная цель -создание полимерных конструкций с бионаправленным йствием, способных заменить отдельные структуры живого организма, в частности сердечно-сосудистой системы. Научная но-зна поставленной задачи заключается в использовании нового подхода создания органа непосредственно в организме пациента счет биофункциональности и биорезорбируемости полимерных конструкций. доказана долгосрочная проходимость полимерных судистых графтов на основе поликапролактона и композиции полигидроксибутирата/валерата и поликапролактона. В экспери-нтах in vitro доказано, что ростовые факторы, инкорпорируемые в состав биодеградируемых графтов, сохраняют свою био-гическую активность. В долгосрочных экспериментах in vivo доказано, что сосудистый эндотелиальный фактор роста ускоряет дотелизацию и улучшает проходимость биодеградируемых полимерных сосудистых графтов.Ключевые слова: биодеградируемые полимеры, сосудистый графт, ростовые факторы. RICICd has large experience in the development of products for cardiovascular surgery, in particular, the bioprosthesis heart valves d blood vessels. Since 2010, under the leadership of the academician of RAS L. S. Barbarash researches to create bioresorbable scular prostheses of small diameter began. the primary purpose -to create polymer structures with bio-directed action capable to lace individual structures of a living organism, in particular, of cardiovascular system. Scientific novelty of the problem lies in using a new proach for creation an organ directly in the patient's body by biofunctional and bioresorbable features of polymer structures. the long-term tency of PCL vascular grafts and PHBV and P...

show abstract

The effects of probiotic bacteria on glycaemic control in overweight men and women: a randomised controlled trial

Cited by 77 publications

References 49 publications

Probiotic Foods and Supplements Interventions for Metabolic Syndromes: A Systematic Review and Meta-Analysis of Recent Clinical Trials

Probiotic Foods and Supplements Interventions for Metabolic Syndromes: A Systematic Review and Meta-Analysis of Recent Clinical Trials

Multiple effects of probiotics on different types of diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials

Obesity and Metabolic Syndrome: Pathophysiological Role of Gut Microbiota and Potential of the Alternative Therapy

Contact Info

Product

Resources

About